Practical Insights on Using BCMA-Targeted Therapies in Multiple Myeloma
Experts discuss the role of BCMA-targeted therapy for patients with multiple myeloma, including their experiences and challenges with implementing these approaches in clinical practice.
Decera Clinical Education Oncology Podcast · Suzanne Lentzsch MD PhD, Joseph Mikhael MD MEd FRCPC FACP
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of:
- Considerations with administration, including access challenges
- Sequencing Therapies
- Future developments with BCMA-targeted therapies
Presenters:
Suzanne Lentzsch, MD, PhD
Professor of Medicine
Division of Hematology/Oncology
Director, Multiple Myeloma and Amyloidosis Program
Columbia University Medical Center
New York, New York
Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor
Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
Phoenix, Arizona
Chief Medical Officer
International Myeloma Foundation
HonorHealth Research Institute
Scottsdale, Arizona
Provided by Clinical Care Options, LLC in partnership with Smart Patients.
Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc.
Link to full program: bit.ly/41YEOO6
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.